Get the Stockscreener App
15.08
4.81%
0.6925
Contineum Therapeutics Inc stock is traded at $15.08, with a volume of 58,697.
It is up +4.81% in the last 24 hours and up +12.22% over the past month.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
See More
Previous Close:
$14.39
Open:
$14.49
24h Volume:
58,697
Relative Volume:
0.21
Market Cap:
$564.16M
Revenue:
$50.00M
Net Income/Loss:
$-59.98M
P/E Ratio:
-6.9072
EPS:
-2.1836
Net Cash Flow:
$-55.54M
1W Performance:
+25.26%
1M Performance:
+12.22%
6M Performance:
+36.98%
1Y Performance:
+294.81%
1-Day Range:
$14.34
$15.66
1-Week Range:
$11.78
$15.66
52-Week Range:
$3.35
$16.33
Contineum Therapeutics Inc Stock (CTNM) Company Profile
Name
Contineum Therapeutics Inc
Sector
Industry
Phone
(858) 333-5280
Address
3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO
Compare CTNM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTNM
Contineum Therapeutics Inc
|
15.09 | 537.99M | 50.00M | -59.98M | -55.54M | -2.1836 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Contineum Therapeutics Inc Stock (CTNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Sep-25-25 | Initiated | Leerink Partners | Outperform |
| Jun-20-25 | Initiated | William Blair | Outperform |
| Oct-22-24 | Initiated | Robert W. Baird | Outperform |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Apr-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-30-24 | Initiated | Stifel | Buy |
View All
Contineum Therapeutics Inc Stock (CTNM) Latest News
Contineum Therapeutics, Inc. Q1 2026 Financial Report: Earnings, Clinical Pipeline Progress, and Forward-Looking Statements 14 - Minichart
Contineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones - BioSpace
Contineum (NASDAQ: CTNM) Q1 loss narrows, cash reaches $246.3M - Stock Titan
Chronic pain data and cash runway to 2029 for Contineum (NASDAQ: CTNM) - Stock Titan
Contineum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Quantisnow
Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock - Investing.com
Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock By Investing.com - Investing.com South Africa
Contineum (NASDAQ: CTNM) CSO trims stake under 10b5-1 plan - Stock Titan
CTNM (NASDAQ: CTNM) affiliate reports multiple 10b5-1 sales by Daniel Lorrain - Stock Titan
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Weekly Voice
Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain - BioSpace
Contineum reports phase 1b trial results for chronic pain drug By Investing.com - Investing.com South Africa
Contineum Therapeutics : PIPE-791 Phase 1b Chronic Pain Trial Topline Data Supplemental Information - marketscreener.com
Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data - TipRanks
Contineum reports phase 1b trial results for chronic pain drug - Investing.com
[ARS] Contineum Therapeutics, Inc. SEC Filing - Stock Titan
Contineum Therapeutics (NASDAQ: CTNM) details 2026 virtual annual meeting - Stock Titan
Positive PIPE-791 chronic pain Phase 1b results for Contineum (NASDAQ: CTNM) - Stock Titan
Contineum’s MS drug falls short in Phase II trial - MSN
Is Contineum (CTNM) stock holding key zones | Q4 2025: EPS Misses ViewsFast Rising Picks - Cổng thông tin điện tử tỉnh Lào Cai
Contineum (CTNM) Stock High Reward Trade (Softens) 2026-04-20Community Trade Ideas - Xã Thanh Hà
Therapeutics Inc Gains Momentum In The Biotech Healthcare Sector - Kalkine Media
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Live Share Price, Invest From India - INDmoney
We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth - Yahoo Finance
Contineum (CTNM) Stock: Risk Assessment (Investors Pile In) 2026-04-18Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Millennium Group (CTNM) reports shared 1,658,349-share stake via Schedule 13G - Stock Titan
Contineum Therapeutics (NASDAQ:CTNM) Stock Price Up 2.2%Here's What Happened - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Bank Watch: Can Contineum Therapeutics Inc stock outperform in a bear marketWeekly Trade Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Contineum Therapeutics CSO sells $56k in CTNM stock - Investing.com UK
Contineum Therapeutics CSO sells $56k in CTNM stock By Investing.com - Investing.com India
Pre-planned stock sale by Contineum (CTNM) chief scientific officer - Stock Titan
Daniel Lorrain sells via 10b5-1; CTNM (NASDAQ: CTNM) Form 144 notice - Stock Titan
Should I Hold Contineum (CTNM) Stock Now | Price at $13.38, Down 0.48%High Attention Stocks - Newser
CTNM Stock Analysis: Contineum Therapeutics Inc posts 4.9 percent gain at 13.7 in recent trading - Newser
CTNM Technical Analysis & Stock Price Forecast - Intellectia AI
Contineum (CTNM) Q2 R&D Jumps 78% - aol.com
MACD Signal: Can Contineum Therapeutics Inc stock outperform in a bear market2026 Volume & Low Volatility Stock Recommendations - baoquankhu1.vn
Guidance Update: Is Contineum Therapeutics Inc currently under institutional pressure2026 Opening Moves & Stepwise Trade Signal Guides - baoquankhu1.vn
Sentiment Review: Is Contineum Therapeutics Inc currently under institutional pressureWeekly Investment Summary & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Companies Like Contineum Therapeutics (NASDAQ:CTNM) Are In A Position To Invest In Growth - simplywall.st
Retail Trends: What is the Moat Score of Contineum Therapeutics Inc2026 Pullbacks & Low Risk Entry Point Guides - baoquankhu1.vn
Contineum Therapeutics (NASDAQ:CTNM) Trading 8.7% HigherStill a Buy? - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal
Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - Defense World
Contineum Therapeutics Inc Stock (CTNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):